Clincosm LogoSign in Get a demo

GLP: Glucagon Like Peptides Receptors Expression in the Stomach of Diabetes Type 2

Sponsor
Assaf-Harofeh Medical Center (Other)
Overall Status
Unknown status
CT.gov ID
NCT00473733
Collaborator
(none)
1
Location

Study Details

Study Description

Brief Summary

Glucagon like peptides receptors expression in the stomach of diabetes type 2 Glucagon like peptides (GLP-1, GLP-2), are hormones secreted by L cells located along the gastrointestinal tract. These hormones are secreted after meals and have some roles in regulating the digestion process, absorption, and sending signals to the brain that regulate food consumption. GLP peptides affect peripheral targets and have an important homeostatic role. GLP-1 decreases the circulatory glucose level and GLP-2 has trophic effects which enable adequate intestine growth.

We aimed in our study to investigate the GLP-1 and GLP-2 receptor expression in different zones of the stomach in diabetes type 2 patients. If there are differences, it might explain the pathological gastric emptying in these patients.

Understanding the function of these peptides may lead to new therapeutic options for diabetic patients with delayed gastric emptying.

Methods: 20 diabetes type 2 patients with symptoms that need upper endoscopy will be included in the study and 20 controls aged 18-70 years. Patients with neurological disease will be excluded. During esophagogastroduodenoscopy 3 biopsies will be taken from the antrum, corpus and cardia. The biopsies will be stored in -70. After RNA extraction the GLP receptors expression will established by real time PCR method. Patients with different expression compared to control will undergo isotopic scan for gastric emptying.

Condition or Disease Intervention/Treatment Phase
  • Procedure: GLP receptors expression
  • Procedure: ESOPHAGOGASTRODUODENOSCOPY
 Phase 4

Study Design

Study Type:
Interventional
Allocation:
Non-Randomized
Intervention Model:
Crossover Assignment
Masking:
None (Open Label)
Primary Purpose:
Diagnostic

Outcome Measures

Primary Outcome Measures

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 70 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • 20 diabetes type 2 patients with symptoms that need upper endoscopy will be included in the study and 20 controls aged 18-70 years
    Exclusion Criteria:
    • Patients with neurological disease will be excluded

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Assaf Harofeh Medical Center Zerifin Israel 70300

    Sponsors and Collaborators

    • Assaf-Harofeh Medical Center

    Investigators

    • Principal Investigator: Efrat Broide, MD, Ethic committee of Asaaf Harofeh Medical Center

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    , ,
    ClinicalTrials.gov Identifier:
    NCT00473733
    Other Study ID Numbers:
    • 65/07
    First Posted:
    May 15, 2007
    Last Update Posted:
    May 15, 2007
    Last Verified:
    Apr 1, 2007
    Keywords provided by , ,
    PATIENTS WITH DIABETES MELLITUS TYPE 2
    UNDERGO UPPER ENDOSCOPY
    BIOPSIES FOR GLP RECEPTORS EXPRESSION
    PCR ANALYSIS
    Additional relevant MeSH terms:
    Diabetes Mellitus
    Diabetes Mellitus, Type 2

    Study Results

    No Results Posted as of May 15, 2007